Stone Rachael M, Haidar Cyrine E, Kornegay Nancy M, Barker Patricia J, Karol Seth E, Wolf Joshua, Hankins Jane S, Relling Mary V, Crews Kristine R
From the Department of Pharmacy and Pharmaceutical Sciences.
Department of Oncology.
Pediatr Infect Dis J. 2024 Aug 7. doi: 10.1097/INF.0000000000004515.
We sought to determine whether Pneumocystis jirovecii pneumonia prophylaxis with sulfamethoxazole-trimethoprim (SMX-TMP) is associated with an increased frequency of acute hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency versus non-G6PD-deficient controls in a pediatric oncology population. There was no statistically significant difference in change in hemoglobin or transfusion requirements after starting SMX-TMP between groups. These findings suggest no increased risk of acute hemolytic anemia with SMX-TMP administered at prophylaxis doses in patients with G6PD deficiency.
我们试图确定，在儿科肿瘤患者中，与非葡萄糖-6-磷酸脱氢酶（G6PD）缺乏的对照组相比，使用磺胺甲恶唑-甲氧苄啶（SMX-TMP）预防耶氏肺孢子菌肺炎是否会增加G6PD缺乏患者急性溶血性贫血的发生频率。两组在开始使用SMX-TMP后血红蛋白变化或输血需求方面无统计学显著差异。这些发现表明，对于G6PD缺乏的患者，以预防剂量使用SMX-TMP不会增加急性溶血性贫血的风险。
